Skip to main content

Table 4 Multivariable analysis of risk factors for total VTE of 29 patients and newly developed VTE of 12 patients (n = 97)

From: Venous thromboembolism in hospitalized patients receiving chemotherapy for malignancies at Japanese community hospital: prospective observational study

  Total VTE Newly developed VTE
Variable OR (95% CI) P OR (95% CI) P
Elderly femalea 3.3 (0.9–12.4) 0.066   -  
BMI ≥25b   -   2.5 (0.5–12.0) 0.25
Reduced mobilityc 4.9 (1.0–24.9) 0.057   -  
6–12 months from tumor onsetd   -   3.0 (0.6–15.8) 0.19
Increased TATe 2.4 (0.9–6.4)f 0.092 3.8 (0.7–20.8)g 0.12
Non-increased PICh 1.2 (0.3–4.0) 0.78   -  
Increased TATe and non-increased PICh 3.0 (1.1–8.2)i 0.034* 9.4 (1.7–51.9)j 0.011*
  1. Abbreviations are as in Table 2. VIF variance inflation factor
  2. * P < 0.05. a ≥ 70 yr. vs. male and female <70 yr., adjusted for reduced mobility and non-increased PIC with increased TAT (VIF, 1.0). bAdjusted for 6–12 months from tumor onset, and non-increased PIC with increased TAT (VIF, 1.0). cAdjusted for elderly female and non-increased PIC with increased TAT (VIF, 1.0). dAdjusted for BMI ≥25 and non-increased PIC with increased TAT (VIF, 1.1). e ≥ 2.1 ng/mL. fAdjusted for elderly female and non-increased PIC (VIF, 1.1). gAdjusted for BMI ≥25 and 6–12 months from tumor onset (VIF, 1.1). h < 1.8 ng/mL, adjusted for elderly female and increased TAT (VIF, 1.2). iAdjusted for elderly female and reduced mobility (VIF, 1.0). jAdjusted for BMI ≥25 and 6–12 months from tumor onset (VIF, 1.1)